Serum macrophage migration inhibitory factor levels are correlated with response to tocilizumab therapy in patients with rheumatoid arthritis

By Kasama Tsuyoshi   Isojima Sakiko   Umemura Masayu   Tsukamoto Hiroyuki   Tokunaga Takehiro   Furuya Hidekazu   Yanai Ryo   Takahashi Ryo   Nakamura Masanori   Inagaki Katsunori  

Rheumatology International, Vol. 34, Iss. 3, 2014-03 ,pp. : 429-433

Springer Publishing Company

Access to resources Recommend Favorite

Necrotizing fasciitis in a patient with rheumatoid arthritis treated with tocilizumab

By Yoshida Akiko  

Modern Rheumatology, Vol. 22, Iss. 2, 2012-04 ,pp. : 317-318

Springer Publishing Company

Access to resources Recommend Favorite

Rheumatoid arthritis and the evolution of therapy: from symptomatic to bench-to-bedside biological drugs

By Lukas Cédric   Combe Bernard   Morel Jacques  

Future Rheumatology, Vol. 2, Iss. 2, 2007-04 ,pp. : 143-152

Future Medicine

Access to resources Recommend Favorite

Improvement of health status evaluated by Arthritis Impact Measurement Scale 2 (AIMS-2) and Short Form-36 (SF-36) in patients with rheumatoid arthritis treated with tocilizumab

By Fusama Mie  

Modern Rheumatology, Vol. 23, Iss. 2, 2013-03 ,pp. : 276-283

Springer Publishing Company

Access to resources Recommend Favorite

IL-6 Signaling and its Blockade with a Humanized Anti-Interleukin-6 Receptor Antibody in Rheumatoid Arthritis: Advent of a New and Innovative Therapeutic Drug, Tocilizumab

By  

Current Rheumatology Reviews, Vol. 7, Iss. 4, 2011-11 ,pp. : 288-300

Bentham Science Publishers

Access to resources Recommend Favorite